Clinical Significance of BTLA, CD27, CD70, CD28 and CD80 as Diagnostic and Prognostic Markers in Ovarian Cancer

Świderska, Janina; Kozłowski, Mateusz; Gaur, Maria; Pius-Sadowska, Ewa; Kwiatkowski, Sebastian; Cymbaluk‐Płoska, Aneta

doi:10.3390/diagnostics12020251

Cited by 7 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The older the age, the more gene accumulation (Franco et al, 2019;Szilard, 1959); therefore, it was speculated that age may increase the expression of BTLA by cumulative mutations, which promotes the occurrence and development of cancer. At present, the clinical research on BTLA is not sufficient, but only from the existing test, the separate expression of BTLA is associated with the prognosis of patients with nonsmall cell lung cancer (NSCLC) and OV (Li et al, 2020;Świderska et al, 2022), which is consistent with the results of BTLA pan-cancer prognosis analysis, reflecting the potential of BTLA as a prognostic marker for cancer patients to evaluate the survival status of patients. In these cancers, the expression of BTLA is often a poor prognostic factor, which is consistent with the biological characteristics of BTLA inhibiting lymphocytes and providing some evidence for the efficacy of immune-checkpoint inhibitors targeting BTLA.…”

Section: Discussionmentioning

confidence: 53%

A pan-cancer analysis of the biological function and clinical value of BTLA in tumors

Jiang¹,

He²,

WANG³

et al. 2023

Biocell

View full text Add to dashboard Cite

B and T-lymphocyte attenuator (BTLA) plays an immunosuppressive role by inhibiting T-and B-cell functions.BTLA is associated with a variety of diseases, especially cancer immunity. However, the function of BTLA in various cancers and its clinical prognostic value have still not been comprehensively analyzed. This study aimed to identify the relationship between BTLA and cancer from the perspectives of differences in BTLA expression, its clinical value, immune infiltration, and the correlation with immune-related genes in various cancers. Data regarding mRNA expression, miRNA expression, lncRNA expression, and clinical data of patients of 33 existing cancers were collected from the TCGA database. Target miRNA of BTLA and the lncRNA that interacts with the target miRNA were obtained from the StarBase database. Based on bioinformatics analysis methods, the relationship between various types of cancers and BTLA was thoroughly investigated, and a competing endogenous RNA network of BTLA, target miRNA, and interacting lncRNA was constructed. The Kaplan-Meier (KM) prognostic analysis of BTLA and target miRNA (has-miR-137) in various types of cancers was completed using the KM plotter. BTLA expression varied in different cancers, with statistical significance in nine cancer types. KM plotter to analyze the overall survival (OS) and regression-free survival prognosis of cancer patients revealed that the BTLA expression was statistically different in the OS of 11 types of cancers out of 21 types of cancers; the OS of 8 type of cancers was also statistically different.Correlation analysis of tumor immune genes revealed a positive correlation of BTLA expression with immunosuppressive gene (CTLA4 and PDCD1) expression. Gene Set Enrichment Analysis showed that BTLA and its co-expressed genes mainly act through biological processes and pathways, including immune response regulation, cell surface receptor signaling pathway, antigen binding, antigen receptor-mediated signaling pathway, and leukocyte migration. BTLA has the potential as a prognostic marker for CLL, COAD, NSCLC, and OV and a diagnostic marker for CLL, COAD, and KIRC. BTLA has a close and complex relationship with the occurrence and development of tumors, and cancer immunotherapy for BTLA is worthy of further analysis.

show abstract

Section: Discussionmentioning

confidence: 53%

A pan-cancer analysis of the biological function and clinical value of BTLA in tumors

Jiang¹,

He²,

WANG³

et al. 2023

Biocell

View full text Add to dashboard Cite

show abstract

“…The interaction of CD70 with its receptor, CD27, results in B- and T-cell activation. In a recent study, Swiderska et al found evidence of a correlation between the serum CD70 concentration and overall survival in patients with ovarian cancer [ 17 ]. The authors also showed that higher concentrations of CD70 in the peritoneal fluid were associated with peritoneal carcinomatosis.…”

Section: Discussionmentioning

confidence: 99%

Loco-Regional Control and Sustained Difference in Serum Immune Protein Expression in Patients Treated for p16-Positive and p16-Negative Head and Neck Squamous Cell Carcinoma

Sandström

Ehrsson

Sellberg

et al. 2023

IJMS

View full text Add to dashboard Cite

The main prognostic factors for patients with head and neck cancer are the tumour site and stage, yet immunological and metabolic factors are certainly important, although knowledge is still limited. Expression of the biomarker p16INK4a (p16) in oropharyngeal cancer tumour tissue is one of the few biomarkers for the diagnosis and prognosis of head and neck cancer. The association between p16 expression in the tumour and the systemic immune response in the blood compartment has not been established. This study aimed to assess whether there is a difference in serum immune protein expression profiles between patients with p16+ and p16- head and squamous cell carcinoma (HNCC). The serum immune protein expression profiles, using the Olink® immunoassay, of 132 patients with p16+ and p16- tumours were compared before treatment and one year after treatment. A significant difference in the serum immune protein expression profile was observed both before and one year after treatment. In the p16- group, a low expression of four proteins: IL12RB1, CD28, CCL3, and GZMA before treatment conferred a higher rate of failure. Based on the sustained difference between serum immune proteins, we hypothesise that the immunological system is still adapted to the tumour p16 status one year after tumour eradication or that a fundamental difference exists in the immunological system between patients with p16+ and p16- tumours.

show abstract

“…BTLA levels in tumor tissue have been linked to poor prognoses for ovarian and breast cancer patients. Another study [15], found that ovarian cancer patients had significantly higher median protein concentrations (BTLA, CD27, CD28, and CD80) in their blood. Recent research linked BTLA to lower immune checkpoint inhibitor patient survival.…”

Section: Investigating the Correlation Of Patient's Serum Levels Usin...mentioning

confidence: 96%

Investigating the Changing Levels of Immune Checkpoint Proteins in The Serum of Breast Cancer Patients

Alrahimi¹,

Yousuf²,

Pushparaj³

et al. 2022

Pharmacophore

View full text Add to dashboard Cite

Breast cancer is the most frequent kind of invasive cancer in women. Biomarker monitoring and prognosis provide outstanding clinical information that may be employed to battle various cancers. This study aimed to examine a variety of biomarkers utilizing a multiplex bead array. BTLA, CD27, CD28, TIM-3, HVEM, CD40, LAG-3, TLR-2, PD-1, CD80, CD86, PDL-1, PDL-2, and ICOS are common biomarker checkpoint proteins found in a selective panel. This panel examined a research group of 59 patients with BC and 17 healthy people. The expression patterns of a handful of the fourteen biomarkers varied considerably between people with BC and healthy controls. With Pvalues of (p= 0.05), (p= 0.02), (p= 0.01), and (p= 0.02), general features of the two groups of malignant and non-malignant patients revealed significant correlations in parameters such as the age of first menstruation, pregnancy, menopausal status, and hormone replacement treatment. With P-values, there was a substantial rise in BTLA, HVEM, TLR-2, and PDL-1 serum levels, as well as a significant drop in CD86. Furthermore, these markers indicated a significant relationship with the clinic-pathological aspects of the patients. With a P-value of 0.0002, both BTLA and HVME showed a statistically significant connection with hormone receptor phenotypes. For ER status, BTLA, CD86, and PDL1 had equivalent significance values of (p= 0.0148), (p= 0.0166), and (p= 0.0001). BTLA was related to lymph node involvement (p=0.0397), whereas TLR2 was associated with HER2 status (p=0.0332). BTLA, HVEM, TLR-2 CD86, and PDL-1 may be valuable biomarkers for cancer monitoring and prognosis.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non commercially, as long as the author is credited and the new creations are licensed under the identical terms.

show abstract

Clinical Significance of BTLA, CD27, CD70, CD28 and CD80 as Diagnostic and Prognostic Markers in Ovarian Cancer

Cited by 7 publications

References 25 publications

A pan-cancer analysis of the biological function and clinical value of BTLA in tumors

A pan-cancer analysis of the biological function and clinical value of BTLA in tumors

Loco-Regional Control and Sustained Difference in Serum Immune Protein Expression in Patients Treated for p16-Positive and p16-Negative Head and Neck Squamous Cell Carcinoma

Investigating the Changing Levels of Immune Checkpoint Proteins in The Serum of Breast Cancer Patients

Contact Info

Product

Resources

About